ReviewSeminars in nephrology2018
Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation.
Review in Seminars in nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- The effect of clinical pharmacist-led pharmaceutical care services on medication adherence, clinical outcomes and quality of life in patients with stroke: a randomised controlled trial.International journal of clinical pharmacy · 2025Trial
- Left Atrial Appendage Occlusion vs Anticoagulants in Dialysis With Atrial Fibrillation.JAMA network open · 2025Article
- Anticoagulation in Patients with End-Stage Renal Disease: A Critical Review.Healthcare (Basel, Switzerland) · 2025Review
- Use of Direct Anticoagulants in Kidney Transplant Recipients: Review of the Current Evidence and Emerging Perspectives.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Review
- Anticoagulation in Chronic Kidney Disease.Drugs · 2024Review
- Clinical Impact of the Use of Warfarin in Patients with Atrial Fibrillation Undergoing Maintenance Hemodialysis.Journal of clinical medicine · 2024Article
- Review
- HAS-BLED Score for Prediction of Bleeding and Mortality After Transcatheter Aortic Valve Replacement.Brazilian journal of cardiovascular surgery · 2023Article
- Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins.Journal of clinical medicine · 2022Article
- Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIKidney international reports · 2022Article
- Article
- Correlation of Nursing Quality and Complications in the Hemodialysis Room as well as Nursing Countermeasures.Journal of healthcare engineering · 2022Article
- Survival Benefit of Anticoagulation Therapy in End Stage Kidney Disease Patients with Atrial Fibrillation: A Single Center Retrospective Study.Medicina (Kaunas, Lithuania) · 2021Article
- Direct Oral Anticoagulant Use in Special Populations: Elderly, Obesity, and Renal Failure.Current cardiology reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Patients with end-stage kidney disease (ESKD) have an elevated incidence of atrial fibrillation (AF) and are at increased risk for thromboembolic events. However, these patients are also at increased risk for bleeding and it is unclear whether they benefit from an oral anticoagulant. Point prevalent on July 1, 2015, only ~28% of dialysis patients with AF were on oral anticoagulation. Warfarin was the most commonly used oral anticoagulant, followed by apixaban, while dabigatran and rivaroxaban were rarely used. This article reviews the current evidence regarding each oral anticoagulant especially as they relate to patients with ESKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.